72 related articles for article (PubMed ID: 38496692)
1. Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.
de Jager VD; Stigt JA; Niemantsverdriet M; Ter Elst A; van der Wekken AJ
NPJ Precis Oncol; 2024 May; 8(1):113. PubMed ID: 38778166
[TBL] [Abstract][Full Text] [Related]
2. The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation.
Man X; Sun X; Chen C; Xiang Y; Zhang J; Yang L
Front Oncol; 2024; 14():1367204. PubMed ID: 38919530
[TBL] [Abstract][Full Text] [Related]
3. First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma.
Luan T; Lin X; Xie X; Yang G; Wang S; Hao J; Zhou C
Anticancer Drugs; 2024 Jun; ():. PubMed ID: 38924456
[TBL] [Abstract][Full Text] [Related]
4. Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report.
Rossi S; Costa R; di Federico A; Lobianco F; D'Angelo R; Asioli GM; De Giglio A; Sperandi F; Guarino M; Rinaldi R; Ardizzoni A; Cenacchi G; Gelsomino F
J Thorac Oncol; 2024 Jun; ():. PubMed ID: 38912994
[TBL] [Abstract][Full Text] [Related]
5. A heterogeneous tumor immune microenvironment of uncommon epidermal growth factor receptor mutant non-small cell lung cancer.
Zhang C; Yang L; Zhao W; Zhu H; Shi S; Chen S; Wang G; Li B; Zhao G
Cancer Sci; 2024 Jun; ():. PubMed ID: 38890815
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib‑induced erythromelalgia: A case report.
Bolzon A; Alessia Guidotti A; Alaibac MAS
Exp Ther Med; 2024 Jul; 28(1):273. PubMed ID: 38800043
[TBL] [Abstract][Full Text] [Related]
7. Onset of takotsubo syndrome induced by osimertinib in a patient with lung adenocarcinoma.
Okamoto S; Shinomiya M
Respir Med Case Rep; 2024; 50():102056. PubMed ID: 38881778
[TBL] [Abstract][Full Text] [Related]
8. Mosaic EGFR exon 20 in-frame insertion pathogenic variants are associated with papular epidermal nevus with "skyline" basal cell layer (PENS).
Bessis D; Poujade L; Cossée M; Boursier G; Barat-Houari M; Tharreau M; Durand L; Aguilar SC; Solassol J; Willems M; Vendrell J
Br J Dermatol; 2024 Jun; ():. PubMed ID: 38828639
[No Abstract] [Full Text] [Related]
9. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.
Guo Q; Feng W; Hu S; Ye J; Wang S; Su L; Zhang Y; Zhang D; Zhang W; Xu J; Wei Y
Medicine (Baltimore); 2023 Aug; 102(34):e34545. PubMed ID: 37653755
[TBL] [Abstract][Full Text] [Related]
10. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib in uncommon
Wang Y; Dorwal P; Rajadurai S; Arulananda S
Transl Lung Cancer Res; 2024 Feb; 13(2):434-442. PubMed ID: 38496692
[TBL] [Abstract][Full Text] [Related]
12. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
[TBL] [Abstract][Full Text] [Related]
13. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
14. A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report.
Shan CG; Wang H; Lin T; Liu D; Wen L; Chen ZJ; Zhen JJ; Lai MY; Zhang L; Zou X; Hong WP; Cai LB
Ann Palliat Med; 2021 May; 10(5):5897-5901. PubMed ID: 33977730
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
Front Oncol; 2021; 11():733276. PubMed ID: 34760695
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
